A 206377
Alternative Names: A-206377Latest Information Update: 25 Jan 2013
At a glance
- Originator Abbott Laboratories
- Class
- Mechanism of Action Endothelin A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 25 Jan 2013 Discontinued - Preclinical for Cardiovascular disorders in USA (unspecified route)
- 27 Aug 1998 Preclinical development for Cardiovascular disorders in USA (unspecified route)
- 02 May 1997 Preclinical development for Undefined indication in USA (unspecified route)